Abstract:Objective: Antiangiogenesis therapy (AAT) has provided substantial benefits regarding improved outcomes and survival for suitable patients in clinical settings. Therefore, the early definition of therapeutic effects is urgently needed to guide cancer AAT. We aimed to optimize the early response monitoring and prediction of AAT efficacy, as indicated by the multi-targeted anti-angiogenic drug sunitinib in U87MG tumors, using noninvasive positron emission computed tomography (PET) molecular imaging strategies of multifactorial bioparameters. Methods: U87MG tumor mice were treated via intragastric injections of sunitinib (80 mg/kg) or vehicle for 7 consecutive days. Longitudinal MicroPET/CT scans with 18F-FDG, 18F-FMISO, 18F-ML-10 and 18F-Alfatide II were acquired to quantitatively measure metabolism, hypoxia, apoptosis and angiogenesis on days 0, 1, 3, 7 and 13 following therapy initiation. Tumor tissues from a dedicated group of mice were collected for immunohistochemical (IHC) analysis of key biomarkers (Glut-1, CA-IX, TUNEL, ανβ3 and CD31) at the time points of PET imaging. The tumor sizes and mouse weights were measured throughout the study. The tumor uptake (ID%/gmax), the ratios of the tumor/muscle (T/M) for each probe, and the tumor growth ratios (TGR) were calculated and used for statistical analyses of the differences and correlations. Results: Sunitinib successfully inhibited U87MG tumor growth with significant differences in the tumor size from day 9 after sunitinib treatment compared with the control group (P < 0.01). The uptakes of 18F-FMISO (reduced hypoxia), 18F-ML-10 (increased apoptosis) and 18F-Alfatide II (decreased angiogenesis) in the tumor lesions significantly changed during the early stage (days 1 to 3) of sunitinib treatment; however, the uptake of 18F-FDG (increased glucose metabolism) was significantly different during the late stage. The PET imaging data of each probe were all confirmed via ex vivo IHC of the relevant biomarkers. Notably, the PET imaging of 18F-Alfatide II and 18F-FMISO was significantly correlated (all P < 0.05) with TGR, whereas the imaging of 18F-FDG and 18F-ML-10 was not significantly correlated with TGR. Conclusion: Based on the tumor uptake of the PET probes and their correlations with MVD and TGR, 18F-Alfatide II PET may not only monitor the early response but also precisely predict the therapeutic efficacy of the multi-targeted, anti-angiogenic drug sunitinib in U87MG tumors. In conclusion, it is feasible to optimize the early response monitoring and efficacy prediction of cancer AAT using noninvasive PET molecular imaging strategies of multifactorial bioparameters, such as angiogenesis imaging with 18F-Alfatide II, which represents an RGD-based probe.

Longitudinal Monitoring Of Tumor Antiangiogenic Therapy With Near-Infrared Fluorophore-Labeled Agents Targeted To Integrin Alpha(V)Beta(3) And Vascular Endothelial Growth Factor

Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin α v β 3 and vascular endothelial growth factor

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy Via Noninvasive Pet Molecular Imaging Strategies of Multifactorial Bioparameters

Optical Imaging Of Integrin Alpha(V)Beta(3) Expression With Near-Infrared Fluorescent Rgd Dimer With Tetra(Ethylene Glycol) Linkers

Early Assessment Of Tumor Response To Gefitinib Treatment By Noninvasive Optical Imaging Of Tumor Vascular Endothelial Growth Factor Expression In Animal Models

In Vivo Near-Infrared Fluorescence Imaging of CD105 Expression During Tumor Angiogenesis

Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer

Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.

Quantitative Ultrasound Molecular Imaging for Antiangiogenic Therapy Monitoring

Serial in Vivo Imaging Using a Fluorescence Probe Allows Identification of Tumor Early Response to Cetuximab Immunotherapy.

SPECT Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts in Vivo

Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft By18f-Flt MicroPET/CT Imaging

Monitoring Anti-Angiogenic Therapy Response in Mouse U87MG Tumor Model Using 18F-FLT and 18F-FDG Micropet/ct

Scintigraphic Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts In Vivo

Positron Emission Tomography And Near-Infrared Fluorescence Imaging Of Vascular Endothelial Growth Factor With Dual-Labeled Bevacizumab

Integrin Αvβ3-Targeted SPECT/CT for the Assessment of Bevacizumab Therapy in Orthotopic Lung Cancer Xenografts.

Non-Invasive Imaging Of Endothelial Progenitor Cells In Tumor Neovascularization Using A Novel Dual-Modality Paramagnetic/Near-Infrared Fluorescence Probe

Monitoring of Tumor Response to Au Nanorod-Indocyanine Green Conjugates Mediated Therapy with Fluorescence Imaging and Positron Emission Tomography

Noninvasive Monitoring of Early Antiangiogenic Therapy Response in Human Nasopharyngeal Carcinoma Xenograft Model Using MRI with RGD-conjugated Ultrasmall Superparamagnetic Iron Oxide Nanoparticles